These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32367687)

  • 1. Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines.
    Valcourt DM; Kapadia CH; Scully MA; Dang MN; Day ES
    Adv Healthc Mater; 2020 Jun; 9(12):e2000110. PubMed ID: 32367687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zebrafish as a preclinical in vivo screening model for nanomedicines.
    Sieber S; Grossen P; Bussmann J; Campbell F; Kros A; Witzigmann D; Huwyler J
    Adv Drug Deliv Rev; 2019; 151-152():152-168. PubMed ID: 30615917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines.
    Ladaycia A; Loretz B; Passirani C; Lehr CM; Lepeltier E
    Adv Drug Deliv Rev; 2021 Mar; 170():44-70. PubMed ID: 33388279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organoids technology for advancing the clinical translation of cancer nanomedicine.
    Zhao DK; Liang J; Huang XY; Shen S; Wang J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The past, present, and future of breast cancer models for nanomedicine development.
    Boix-Montesinos P; Soriano-Teruel PM; Armiñán A; Orzáez M; Vicent MJ
    Adv Drug Deliv Rev; 2021 Jun; 173():306-330. PubMed ID: 33798642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicines: An approach to treat placental insufficiency and the current challenges.
    van Kammen CM; van Woudenberg SJ; Schiffelers R; Terstappen F; Lely AT
    J Control Release; 2023 Aug; 360():57-68. PubMed ID: 37330012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smart transformable nanomedicines for cancer therapy.
    Wang Y; Li S; Wang X; Chen Q; He Z; Luo C; Sun J
    Biomaterials; 2021 Apr; 271():120737. PubMed ID: 33690103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedical engineering: shaping future nanomedicines.
    Luo D; Carter KA; Lovell JF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using imaging modalities to predict nanoparticle distribution and treatment efficacy in solid tumors: The growing role of ultrasound.
    Cooley MB; Wegierak D; Exner AA
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1957. PubMed ID: 38558290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
    Shahiwala A
    Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
    Ozeki T; Tagami T
    Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current landscape of treating different cancers using nanomedicines: Trends and perspectives.
    Morales CS; Grodzinski P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1927. PubMed ID: 37706362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.